Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Clovis Oncology, Inc. (CLVS)

0.0812   0 (0%) 12-20 16:00
Open: 0.0808 Pre. Close: 0.0812
High: 0.0977 Low: 0.078
Volume: 24,212,259 Market Cap: 0(M)

Technical analysis

as of: 2023-03-03 4:48:21 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.15     One year: 0.19
Support: Support1: 0.07    Support2: 0.05
Resistance: Resistance1: 0.13    Resistance2: 0.16
Pivot: 0.1
Moving Average: MA(5): 0.08     MA(20): 0.1
MA(100): 0.45     MA(250): 1.11
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 10.5     %D(3): 9.2
RSI: RSI(14): 31.6
52-week: High: 3.25  Low: 0.04
Average Vol(K): 3-Month: 4,181 (K)  10-Days: 472 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CLVS ] has closed above bottom band by 6.4%. Bollinger Bands are 80.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 36 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.09 - 0.09 0.09 - 0.09
Low: 0.07 - 0.07 0.07 - 0.07
Close: 0.07 - 0.08 0.08 - 0.08

Company Description

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Headline News

Tue, 13 Dec 2022
CLOVIS ONCOLOGY, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) -

Mon, 12 Dec 2022
Cancer drugmaker Clovis files for bankruptcy, hit by falling sales - Reuters

Mon, 12 Dec 2022
Cancer Focused Clovis Oncology Files For Bankruptcy - Yahoo Finance

Mon, 12 Dec 2022
Clovis Oncology Files for Chapter 11 Protection and Enters into ... - Business Wire

Fri, 25 Nov 2022
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why - Nasdaq

Wed, 09 Nov 2022
Why Is Clovis Oncology (CLVS) Stock Down 72% Today? - InvestorPlace

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 145 (M)
Shares Float 143 (M)
% Held by Insiders 1.4 (%)
% Held by Institutions 25.8 (%)
Shares Short 28,490 (K)
Shares Short P.Month 30,770 (K)

Stock Financials

EPS -2.09
EPS Est Next Qtl -1.15
EPS Est This Year -7.58
EPS Est Next Year -2.47
Book Value (p.s.) -2.9
Profit Margin (%) -189.4
Operating Margin (%) -155.2
Return on Assets (ttm) -30.2
Return on Equity (ttm) 0
Qtrly Rev. Growth -19.2
Gross Profit (p.s.) 0.79
Sales Per Share 0.91
EBITDA (p.s.) -1.38
Qtrly Earnings Growth 0
Operating Cash Flow -176 (M)
Levered Free Cash Flow -128 (M)

Stock Valuations

PE Ratio -0.04
PEG Ratio 0
Price to Book value -0.03
Price to Sales 0.08
Price to Cash Flow -0.07

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.